Have you heard about the latest analysis of QIAGEN shares? $QGEN heard? The private bank Berenberg has lowered the price target from 54.90 euros to 48.00 euros, but left the rating at "Buy". Analyst Sam England emphasizes that the fourth quarter was solid, even if the outlook for 2025 was somewhat disappointing.

However, the company's key growth pillars show promising momentum, which could point to long-term growth. In XETRA trading today, QIAGEN shares fell 0.7 percent to 37.24 euros, which means that there is still 28.89 percent upside to the new price target.

Since the beginning of the year, the share has already lost 15.9 percent, which makes the current situation even more interesting. QIAGEN will present its financial results for the first quarter of 2025 on May 5, 2025.

How do you see the further development of the QIAGEN share? Do you think the company can turn things around? 👍

The profit forecasts for the current financial year have risen for 21 of the 40 DAX companies.

According to research by Handelsblatt, analysts have raised their profit estimates for these 7 of the 40 DAX companies by at least five percent in the last three months.

Handelsblatt sheds light on the prospects of these seven companies and their shares with a view to their prospects: the development of earnings this year, the resulting changes in valuation - and how analysts are positioning themselves.

Below is a brief overview, details with further information can be found at "Handelsblatt"

$ENR (-9,65%) The earnings forecasts for Siemens Energy shares are rising most rapidly

$DBK (-10%) Deutsche Bank share: Rising profits cause valuation to fall sharply

For $QGEN Qiagen: Difficult times after the pandemic are over

$VNA (-2,32%) Vonovia makes billions in profit after billions in losses

$ZAL (-7,88%) Zalando: Takeover gives new share price potential

$MTX (-9,58%) MTU: Global market leader generates stable earnings

$DTE (-4,46%) Deutsche-Telekom: Unusually strong vote from analysts

Source / Graphics: Handelsblatt, 18.02.25

Construction of a biotech ETF🧬🚀

I'm a fan of the whole topic and don't really like the sector ETFs on the market in terms of costs and performance. That's why I've dared to construct my own "biotech ETF". I've written down my thought process here and hope you enjoy it a little 😉

1. focus areas according to growth and profitability

The percentage distribution of focus areas is based on an analysis of the growth and profitability potential of each therapeutic area within the biotechnology industry, taking into account various market conditions and dynamics. The reasons for this distribution are as follows:

• Oncology (25%): The oncology market is a large and rapidly growing market due to the high prevalence of cancer and increasing demand for innovative cancer therapies. The growth potential is supported by the continuous introduction of new cancer drugs and therapies.

• Neurology (20%): Although the neurology market is smaller compared to the oncology market, it still offers considerable potential for growth and profitability. The increasing prevalence of neurodegenerative diseases and the need for novel treatment approaches contribute to this potential.

• Immunology (15%): Immunology is an established market with a wide range of therapies for various autoimmune diseases and cancers. Although the market is relatively saturated, advances in immunotherapy continue to offer opportunities for growth and profitability.

• Infectious diseases (20%): The infectious diseases market has gained significant importance due to global health crises such as the COVID-19 pandemic. The increasing demand for vaccines, antiviral therapies and diagnostic tests to combat infectious diseases is contributing to robust growth and profitability potential.

• Cardiovascular diseases (10%): Although the cardiovascular disease market is not growing as fast as other areas, it remains a significant market with some growth potential. Advances in the treatment and prevention of cardiovascular diseases could contribute to further growth.

Genetic diseases (10%): The market for genetic diseases is smaller but highly specialized and growing thanks to advances in genomic research and genome editing technologies. The increasing demand for personalized therapies for rare genetic diseases is contributing to stable growth.

By taking into account market size, growth potential and profitability, we have determined a percentage distribution of focus areas that reflects the attractiveness of each area for investment in the Biotech ETF.

2. selection of companies and their focus areas

Based on the evaluation of the focus areas, we have selected ten biotech companies that cover a broad range of therapeutic areas and hold leading positions in their respective focus areas. The companies and their focus areas as well as the percentage distribution are as follows:

• Amgen ($AMGN (-4,41%)):

Introduction: Amgen is a leading global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. The company is known for its breakthrough developments in oncology, immunology and genetics.

Focus areas:

Oncology: 30%

Immunology: 20%

Cardiovascular diseases: 20%

• Genetic diseases: 30%

• Regeneron Pharmaceuticals ($REGN (-5,25%)):

Introduction: Regeneron Pharmaceuticals is a biopharmaceutical company focused on the development of drugs for serious diseases. The company is known for its pioneering research and development in the fields of oncology, neurology, immunology and infectious diseases.

Focus areas:

Oncology: 30%

Neurology: 30%

Immunology: 20%

• Infectious diseases: 20%

• Vertex Pharmaceuticals ($VRTX (+0,82%)):

Introduction: Vertex Pharmaceuticals is a leader in the development of therapies for rare genetic diseases. The company is dedicated to researching and developing drugs to improve the lives of patients with genetic disorders.

Focus areas:

• Genetic diseases: 100%

• Intellia Therapeutics ($NTLA (-3,19%)):

Introduction: Intellia Therapeutics is a pioneer in the field of genome editing, utilizing CRISPR/Cas9 technology to develop therapies for genetic diseases, oncology and infectious diseases. The company strives to create the next generation of gene therapies.

Focus areas:

Genetic diseases: 50%

Oncology: 30%

• Infectious diseases: 20%

• Biogen Inc. ($BIIB (-5,19%)):

Introduction: Biogen is a leading global biotechnology company focused on the research and development of therapies for neurological diseases. The company has made some of the most significant breakthroughs in the treatment of diseases such as multiple sclerosis and Alzheimer's disease.

Focus areas:

• Neurology: 100%

• Moderna, Inc. ($MRNA (-1,33%)):

Introduction: Moderna is an innovative biopharmaceutical company focused on the development of mRNA therapies and vaccines. The company has attracted worldwide attention for the development of an mRNA vaccine against COVID-19.

Focus areas:

Oncology: 70%

• Infectious diseases: 30%

• Illumina, Inc. ($ILMN (-2,37%)):

Introduction: Illumina is a leading provider of genomics and genomic analysis technologies. The company is revolutionizing genomics by developing cutting-edge sequencing technologies and making significant contributions to genetic disease research.

Focus areas:

• Genetic diseases: 100%

• CRISPR Therapeutics AG ($CRSP (-0,34%)):

Introduction: CRISPR Therapeutics is a leader in the application of CRISPR/Cas9 genome editing technologies to treat genetic diseases. The company has the potential to revolutionize the way we treat genetic diseases.

Focus areas:

• Genetic diseases: 100%

• Alexion Pharmaceuticals, Inc.$n/a): (ISIN: US0153511094)

Introduction: Alexion Pharmaceuticals is a biopharmaceutical company focused on developing therapies for rare and life-threatening diseases. The company has a strong presence in the fields of neurology and immunology.

Focus areas:

Neurology: 40%

• Immunology: 60%

• Qiagen N.V. ($QGEN):

Introduction: Qiagen is a global leader in molecular diagnostics and research products. The company is known for its innovative technologies to diagnose infectious diseases and support life science research.

Focus areas:

Infectious diseases: 100%

This selection of companies represents a diverse range of focus areas and positions in the biotechnology industry and enables

3. weighting of the ETF based on focus areas and companies

Finally, we determined the allocations for each stock based on its exposure to the focus areas and its relative importance within the portfolio. We considered both the growth and profitability potential of each focus area. The final allocation of stocks is as follows:

Regeneron Pharmaceuticals (ticker: REGN): 25%

Moderna, Inc. (Ticker: MRNA): 18%

Intellia Therapeutics (Ticker: NTLA): 16%

Amgen (Ticker: AMGN): 16%

Alexion Pharmaceuticals, Inc (Ticker: ALXN): 10%

Biogen Inc (Ticker: BIIB): 6%

Qiagen N.V. (Ticker: QGEN): 5%

Vertex Pharmaceuticals (Ticker: VRTX): 2%

Illumina, Inc. (Ticker: ILMN): 2%

CRISPR Therapeutics AG (Ticker: CRSP): 2%

This weighting ensures that the portfolio has a good balance between different focus areas as well as an appropriate exposure to the leading companies in the biotechnology industry.

By considering market size, growth potential and profitability, we have determined a percentage distribution of focus areas that reflects the attractiveness of each area for investment in the biotech ETF.

I look forward to receiving feedback and assessments ✌️😉

Your Value Willi

How can a Dutch company be in the Dax? $QGEN

In Germany, a company that does not have its legal seat in Germany can be
has can be included in the Dax under two conditions:

1. a company could then gain access to the leading index if part of the management is located in DE.

2. inclusion in the Dax is also possible if at least 33 percent of global share trading takes place on German stock exchanges.

Qiagen's operational headquarters are located in Hilden near Düsseldorf.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗡𝗲𝘄𝘀 🗞️

𝗘𝗿𝘄𝗲𝗶𝘁𝗲𝗿𝘁𝗲𝗿 𝗗𝗔𝗫 / 𝗕𝗠𝗪 𝗶𝗻 𝗞𝗹𝗶𝗺𝗮𝗼𝗳𝗳𝗲𝗻𝘀𝗶𝘃𝗲 / 𝗕𝗶𝘁𝗰𝗼𝗶𝗻 𝗶𝗻 𝗘𝗹 𝗦𝗮𝗹𝘃𝗮𝗱𝗼𝗿

𝗜𝗣𝗢𝘀 🔔

𝙃𝙮𝙪𝙣𝙙𝙖𝙞 𝙃𝙚𝙖𝙫𝙮 𝙄𝙣𝙙𝙪𝙨𝙩𝙧𝙞𝙚𝙨 - South Korean shipbuilder Hyundai Heavy Industries has raised $935 after pricing newly issued securities at the high end of the price range. Most of the fresh capital is expected to go into new technologies, such as environmentally friendly ships or 'smart shipyards'.

The listing is scheduled to take place on KOSPI on Sept. 16.

𝗠𝗮𝗿𝗸𝗲𝘁𝘀 🏛️

𝗗𝗔𝗫 - On Friday evening after the US close, the new members of the DAX ($GDAXI ) were announced. Moving up are: Airbus ($AIR (-8,31%)), Siemens Healthineers ($SHL (-5,55%)), Sartorius ($SRT (-4,56%)), Zalando ($ZAL (-7,88%)), Symrise ($SYIEY (+0,85%)), Porsche ($PAH3 (-3,65%)), HelloFresh ($HFG (-6,83%)), Brenntag ($BNR (-5,98%)), Puma ($BNR) and Qiagen ($QIA).

𝗕𝗠𝗪 ($BMW (-5,51%)) - Group CEO Zipse is going on the sustainability offensive. The Group is to reduce its emissions by 40% by 2030. In addition, half of all materials are to be recycled. In addition, battery cells are to be purchased for around 22 billion euros in the coming years. That would be twice as many as previously planned.

𝗖𝗿𝘆𝗽𝘁𝗼 💎

𝗕𝗶𝘁𝗰𝗼𝗶𝗻 ($BTC-EUR (-4,49%)) - As of Tuesday, bitcoin is legal tender in El Salvador. This makes El Salvador the first country to take this step. The corresponding law was passed three months ago and comes into force tomorrow. It stipulates that every merchant must accept Bitcoin as a means of payment if they are technically capable of doing so. In addition, it should also be possible to pay taxes in Bitcoin.

Those who download the digital wallet "Chivo" will receive a starting credit of $30.

Have a good start to the week 😊

𝗠𝗮𝗿𝗸𝗲𝘁 𝗡𝗲𝘄𝘀 🗞️

𝗗𝗔𝗫 𝗘𝗿𝘄𝗲𝗶𝘁𝗲𝗿𝘂𝗻𝗴 / 𝗪𝗵𝗮𝘁𝘀𝗔𝗽𝗽 𝘃𝗼𝗿 𝗦𝘁𝗿𝗮𝗳𝗲 / 𝗕𝗶𝗻𝗮𝗻𝗰𝗲

𝗘𝘅-𝗗𝗮𝘁𝗲𝘀 📅

Today, BlackRock ($BLQA) and Stanley Black Decker ($SWT) are trading ex-dividend.

𝗜𝗣𝗢𝘀 🔔

𝗥𝗲𝗱𝗱𝗶𝘁- Insiders report that the internet platform wants to go public in early 2022. The valuation is currently around $15 billion. The company is currently still looking for advisors to assist with the IPO.

The company declined to comment.

𝗠𝗮𝗿𝗸𝗲𝘁𝘀 🏛️

𝗗𝗔𝗫 𝟰𝟬 - Tonight after the U.S. close, it will be decided which companies will be promoted to the newly expanded DAX. Nine of the ten companies are as good as decided, with the decision alone as to whether Qiagen ($QIA) or Beiersdorf ($BEI (-0,89%)) will be the last to move up, does not yet appear to have been decided. The decision will be based on the company's stock market value.

The actual implementation will take place on September 20.

𝗪𝗵𝗮𝘁𝘀𝗔𝗽𝗽 - The Facebook subsidiary ($FB2A (-4,44%) ) is being asked to pay up in Ireland. It will incur a fine of 225 million euros for lack of transparency in the sharing of personal data. The penalty relates to a case from 2018.

WhatsApp considers the penalty to be unreasonable and announced that it would appeal.

𝗖𝗿𝘆𝗽𝘁𝗼 💎

𝗕𝗶𝗻𝗮𝗻𝗰𝗲 - The crypto platform may be facing a tough time in Singapore. According to the report, the city-state's financial regulator has placed Binance on the "Investor Alert List." That is, the platform cannot now make regulated or licensed payment orders. In addition, Binance is facing growing compliance issues in the UK, Europe and Japan.

Have a great Friday ✌️

It is evtl further tested 😅